ANVS
Annovis Bio, Inc.
Key Financials
Operating Income
$-29695258
↓ 11.2%
Revenue
$0
NaN%
Net Income
$-28854197
↓ 17.3%
Total Assets
$21.1M
↑ 51.4%
EPS (Diluted)
$-1.40
↑ 39.4%
Shareholders' Equity
$16.9M
↑ 81.0%
Operating Cash Flow
$-25619703.00
↓ 17.0%
Total Liabilities
$4.2M
↓ 8.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEF 14A | 9/11/2026 | View on SEC |
| PRE 14A | 8/25/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 7/29/2026 | View on SEC |
| 8-K | 7/10/2026 | View on SEC |
| 8-K | 6/17/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| 8-K | 5/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANVS |
| Company Name | Annovis Bio, Inc. |
| CIK | 1477845 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 484-875-3192 |